Skip to main content

Table 2 Univariate and multivariate analysis of oncologic risk factors correlating with progression-free survival and overall survival

From: The role of diabetes in metastatic melanoma patients treated with nivolumab plus relatlimab

Covariate

Univariate analysis

Multivariate analysis

 

p-value

HR

95% CI

p-value

HR

95% CI

PFS

Gender

0.544

1.168

0.705–1.935

0.614

1.145

0.676–1.936

T2D

0.019

1.285

1.040–1.586

0.035

1.680

1.036–2.720

First-line treatment

0.033

0.607

0.384–0.960

0.050

0.614

0.377–1.000

ECOG PS > 2

0.660

1.131

0.651–1.966

0.345

1.343

0.727–2.476

LDH

0.002

1.906

1.253–2.900

0.021

1.706

1.080–2.692

OS

Gender

0.780

1.085

0.610–1.930

0.613

1.165

0.643–2.108

T2D

0.032

1.310

1.022–1.679

0.050

1.727

1.000–2.981

First-line treatment

0.185

0.698

0.410–1.189

0.249

0.719

0.409 – 1.261

ECOG PS > 2

0.835

1.074

0.548–2.105

0.311

1.472

0.696–3.110

LDH

0.0001

2.683

1.617–4.451

0.0007

2.572

1.493–4.430